Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions

American Journal of Clinical Dermatology, Journal Year: 2023, Volume and Issue: 24(4), P. 521 - 540

Published: May 4, 2023

Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus [SLE]) or the skin only (cutaneous [CLE]). Typical combinations clinical, histological and serological findings define clinical subtypes CLE, yet there is high interindividual variation. Skin lesions arise in course triggers such as ultraviolet (UV) light exposure, smoking drugs; keratinocytes, cytotoxic T cells plasmacytoid dendritic (pDCs) establish self-perpetuating interplay between innate adaptive immune system pivotal for pathogenesis CLE. Therefore, treatment relies on avoidance UV protection, topical therapies (glucocorticosteroids, calcineurin inhibitors) rather unspecific immunosuppressive immunomodulatory drugs. Yet, advent licensed targeted SLE might also open new perspectives management The heterogeneity CLE be attributable to individual variables we speculate prevailing inflammatory signature defined by either cells, B pDCs, strong lesional type I interferon (IFN) response, above suitable predict therapeutic response treatment. pretherapeutic assessment infiltrate could stratify patients with refractory T-cell-directed (e.g. dapirolizumab pegol), B-cell-directed belimumab), pDC-directed litifilimab) IFN-directed anifrolumab). Moreover, Janus kinase (JAK) spleen tyrosine (SYK) inhibitors broaden armamentarium near future. A close interdisciplinary exchange rheumatologists nephrologists mandatory optimal best strategy.

Language: Английский

---

Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)

Journal of Personalized Medicine, Journal Year: 2023, Volume and Issue: 13(4), P. 691 - 691

Published: April 20, 2023

To assess the efficacy of belimumab in joint and skin manifestations a nationwide cohort patients with SLE.

Language: Английский

---

Organ-based characterization of B cells in patients with systemic lupus erythematosus

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 23, 2025

Systemic lupus erythematosus (SLE) is a chronic, inflammatory, and progressive autoimmune disease. The unclear pathogenesis, high heterogeneity, prolonged course of the disease present significant challenges for effective clinical management patients. Dysregulation immune system disruption tolerance, particularly through abnormal activation B lymphocytes production excessive autoantibodies, lead to widespread inflammation tissue damage, resulting in multi-organ impairment. Currently, there no systematic review that examines specificity cell characteristics pathogenic mechanisms across various organs. This paper reviews current research on cells patients summarizes distinct different By integrating manifestations organ damage with focus organ-specific features cells, we provide new perspective enhancing efficacy lupus-targeted therapy strategies.

Language: Английский

---

B Cells Infiltration Potentially Responded Better to Systemic Corticoids in Oral Lichen Planus and Oral Lichenoid Lesions

Inflammation, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 9, 2024

Language: Английский

---

The Possible Clinical Significance of a Decreased Serum Level of Soluble PD-L1 in Discoid Lupus Erythematosus, but Not in Subacute Cutaneous Lupus Erythematosus—A Pilot Study

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(17), P. 5648 - 5648

Published: Aug. 30, 2023

Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease with various clinical forms, including the subtypes of discoid (DLE) and subacute cutaneous (SCLE). The altered function programmed cell death 1/programmed ligand 1 (PD-1/PD-L1) axis in CLE pathogenesis has been suggested. Here, soluble forms PD-1 (sPD-1) PD-L1 (sPD-L1) were explored untreated DLE SCLE. Levels sPD-1 sPD-L1 determined by enzyme-linked immunosorbent assay serums 21 DLE, 18 SCLE, 13 systemic (SLE) patients 20 healthy controls (HCs). Differences between patient groups HCs, association activity symptoms sPD-1/sPD-L1 levels analyzed Mann-Whitney U-test Spearmann's correlation. Regarding levels, no statistically significant differences found SCLE groups, nor compared to HCs. As for sPD-L1, a significantly lower level was group HC (p = 0.027 p 0.009, respectively). In SLE, higher HCs 0.002). No symptom CLE. Alterations inhibitory effect on T-cell might elucidate

Language: Английский

---

CXCL13 as a possible immunological surrogate marker of dermatomyositis: higher levels of CXCL13 in dermatomyositis than polymyositis

Journal of St Marianna University, Journal Year: 2023, Volume and Issue: 14(2), P. 103 - 115

Published: Jan. 1, 2023

CXCL13 is a chemokine involved in the pathophysiology of connective tissue diseases by contributing to ectopic lymphoid follicle formation. 59 patients with new-onset dermatomyositis (DM) (n = 42) / polymyositis (PM) 17) were evaluated from October 2018 March 2023 for clinical and pathophysiological significance DM PM at our university hospital. Plasma levels measured ELISA, their correlation characteristics treatment was analyzed. higher than those (P 0.016), these subsets could be differentiated using cut-off value 81.1 U/L (area under curve 0.8). In positive anti-aminoacyl-tRNA synthetase antibodies, had significantly plasma 0.001). correlated serum creatine kinase 0.007), but not KL-6 0.288) DM. Following treatment, decreased 0.008). conclusion, high, especially can an important implicated DM, which serves as novel immunological marker disease activity

Language: Английский

---